Symbiotec Q1 FY27: Consol. Revenue ₹218.2 Cr, PAT ₹14.1 Cr

Symbiotec Pharmalab Limited announced its financial results for Q1 FY27, reporting consolidated revenues of ₹218.2 Cr and a consolidated PAT of ₹14.1 Cr. The API business delivered steady performance with 6% year-on-year growth, achieving operating revenue of ₹215.3 Cr and EBITDA of ₹65.8 Cr. Consolidated EBITDA was ₹45.2 Cr, impacted by ₹35 Cr in expenses from new businesses yet to generate revenue. Operationally, the company successfully completed EUGMP and USFDA audits, filed its first ANDA for Complex Injectables, and secured significant take-or-pay agreements for Biotech - CDMO services. Total gross capex is estimated at ₹1,666 Cr by FY27, with ₹1,000 Cr allocated to new revenue-generating businesses. Net Debt reduced to ₹326 Cr post IPO proceeds, reflecting management's focus on future growth engines.